Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. US Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help

  1. Font size

    Reduce font size Increase font size  
 

Press Releases

 
  1. Press Releases
  2. Press Statements
  3. SANOFI US PRESS KIT
  4. News Alerts
  5. Media Contacts
  6. Social Media
  7. Photos & Videos
 

Contact Us

Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807



 

Our news releases are listed in chronological order and archived by year. To find news releases on a specific topic, utilize the search function.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

Category 

Oct 16, 2017
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
- Late-breaking oral abstract presented at the World Congress of Gastroenterology -
Oct 11, 2017
Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
- Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease -
Oct 5, 2017
Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
- Praluent continues to be available to patients in the U.S. -
Sep 28, 2017
Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
- First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis -
Sep 20, 2017
Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS
- In preclinical studies, trispecific antibodies show exceptional potency against diverse HIV viruses -
 

2017 News Releases

Share

Print Email page RSS
print email rss

Email information entered to email a page is only used to send the message and is not retained.

Corporate Information

Corporate Information